1	DIAGNOSTIC ACCURACY OF NON-INVASIVE DETECTION OF SARS-COV-2
2	INFECTION BY CANINE OLFACTION
3	
4	
5	Dominique GRANDJEAN ¹ , Caroline ELIE ^{2,3} , Capucine GALLET ¹ , Clotilde JULIEN ¹ , Vinciane ROGER ¹ , Loïc
6	DESQUILBET ¹ , Guillaume ALVERGNAT ⁴ , Séverine DELARUE ⁷ , Audrey GABASSI ⁷ , Marine MINIER ⁷ , Laure
7	CHOUPEAUX ² , Solen KERNEIS ^{5,6} , Constance DELAUGERRE ⁷ , Jérôme LE GOFF ⁷ , Jean-Marc TRELUYER ^{2,3}
8	
9	Affiliations of the authors
10	
11 12	⁴ Ecole Nationale Vétérinaire d'Alfort (Alfort School of Veterinary Medicine), University Paris-Est, Maisons-Alfort France
13	² Unité de Recherche Clinique / Centre Investigation Clinique, APHP, Hôpital Necker-Enfants malades,
14	F-75015 Paris, France
15	³ Université de Paris, EA 7323 Pharmacologie et thérapeutique de l'enfant et de la femme enceinte,
16	F-75015 Paris, France
17	⁴ International Affairs Bureau, Ministry of Interior of the UAE, United Arabian Emirates
18	⁵ Université de Paris, INSERM, IAME, F-75018 Paris, France
19	[°] Equipe de Prévention du Risque Infectieux, AP-HP, Hôpital Bichat, F-75018 Paris, France
20	Śervice de Virologie, AP-HP, Hopital Saint Louis, F-75010 Paris, France
21	
22	Corresponding Author: Jean-Marc Tréluyer, MD, Unité de Recherche Clinique, Hôpital Necker-
23	Enfants malades, 149, rue de Sèvres, 75015 Paris, France; Phone: +33 1 58413481; Fax: +33 1
24	44495950;
25	Email: jean-marc.treluyer@aphp.fr
26	Running title: Detection of SARS-CoV-2 infection by canine olfaction

28 ABSTRACT

- 29 BACKGROUND
- 30 Throughout the COVID-19 pandemic, testing individuals remains a key action. One approach to rapid
- 31 testing is to consider the olfactory capacities of trained detection dogs.
- 32 METHODS
- 33 Prospective cohort study in two community COVID-19 screening centers. Two nasopharyngeal swabs
- 34 (NPS), one saliva and one sweat samples were simultaneously collected. The dog handlers (and the

dogs...) were blinded with regards to the Covid status. The diagnostic accuracy of non-invasive

- 36 detection of SARS-CoV-2 infection by canine olfaction was assessed as compared to nasopharyngeal
- 37 RT-PCR as the reference standard, saliva RT-PCR and nasopharyngeal antigen testing.
- 38 RESULTS

39 335 ambulatory adults (143 symptomatic and 192 asymptomatic) were included. Overall, 109/335 40 participants tested positive on nasopharyngeal RT-PCR either in symptomatic (78/143) or in 41 asymptomatic participants (31/192). The overall sensitivity of canine detection was 97% (95% CI, 92 to 99) and even reached 100% (95% CI, 89 to 100) in asymptomatic individuals compared to NPS RT-42 43 PCR. The specificity was 91% (95% CI, 72 to 91), reaching 94% (95% CI, 90 to 97) for asymptomatic 44 individuals. The sensitivity of canine detection was higher than that of nasopharyngeal antigen 45 testing (97% CI: 91 to 99 versus 84% CI: 74 to 90, p=0.006), but the specificity was lower (90% CI: 84 46 to 95 versus 97% CI: 93 to 99, p=0.016).

47 CONCLUSIONS

48 Non-invasive detection of SARS-CoV-2 infection by canine olfaction could be one alternative to NPS
49 RT-PCR when it is necessary to obtain a result very quickly according to the same indications as
50 antigenic tests in the context of mass screening.

52 INTRODUCTION

Facing the COVID-19 crisis, early and efficient screenings are needed to limit the spread of the virus, allowing for the prompt isolation of positive individuals, a key action in this constant fight. Presently, most ongoing diagnostic COVID-19 testing involves nasopharyngeal sampling for RT-PCR, nasopharyngeal point-of-care antigen testing or saliva RT-PCR to identify the pathogen. Nasopharyngeal sampling for RT-PCR is the reference test but has the drawback of invasiveness and discomfort (nasopharyngeal sampling) and/or delay (RT-PCR) in obtaining the result.

59 Volatile organic compounds (VOC) have the potential to become a revolutionary and non-invasive 60 approach to medical diagnostic in humans for conditions like cancer and degenerative or infectious 61 diseases. Aksenov [1,2] studied the VOCs produced by cultures of B-lymphocytes infected by three 62 influenza viruses: avian H9N2, avian H6N2 and human H1N1. The families of collected VOCs turned 63 out to be unique and specific to each viral subtype. The authors concluded that the minor alterations 64 induced by the virus on the cell's genome expression led to a specific change in the production of 65 VOCs in the cellular metabolism. Recently, Abd El Qader [3] showed the specificity of bacterial or 66 viral species in the VOCs produced by infected cell cultures. Schivo [4] also identified a specific 67 volatilome on airway cells infected by a rhinovirus. Canine olfactory detection capacities have been 68 utilized for years in police enforcement to detect narcotics or forensic remains, explosives, bank 69 notes, for human search and rescue missions and even to locate landmines.

Our hypothesis, the object of our previous proof of concept [5], was based on the potential excretion of specific VOCs in the sweat, induced by SARS-CoV-2 cellular actions or replications generating VOCs that the dogs can detect.

The objective of this prospective blinded multicenter study was to compare the diagnostic accuracy of the detection of SARS-CoV-2 infection by canine olfaction with the current reference standard (nasopharyngeal RT-PCR) and two alternate diagnostic strategies (nasopharyngeal antigenic test and saliva RT-PCR) in community testing centers.

78

79 MATERIALS AND METHODS

This research is part of the "SALICOV-APHP" study (Evaluation of a strategy of SARS-CoV-2 infection testing on a general population, based on the utilization of new detection or diagnostic orientation approaches), promoted by Assistance Publique-Hôpitaux de Paris, France. The SALICOV-APHP study was approved the Protection of Persons Committee (CPP) Ile-de France III (number 3840-NI) and is registered on clinicaltrial.gov (NCT04578509). The protocol was approved for the dogs by the committee on the ethics of animal experiments of the Ecole Nationale Vétérinaire d'Alfort. All research procedures were employed in accordance with the relevant guidelines and regulations.

87 <u>Recruitment of participants</u>

Participants were recruited from two COVID screening centers in Paris piloted by APHP. Informed consent was obtained from all subjects. Eligible persons received detailed oral and written information[6]. Participants were prospectively enrolled if they were not opposed to participating in the study. The following data were collected: age, gender, medical background, current symptoms (temperature higher than 37.8°C, chills, cough, rhinorrhea, muscular pain, loss of olfaction or taste, persisting headache, severe asthenia, etc.) and their onset date, alcohol/coffee/food/tobacco consumption or tooth cleaning within 2 hours and 24 hours prior to the test.

95 Samples

96 Sweat samples were collected by dedicated APHP sampling teams by asking the participants to place 97 two sterile surgical compresses under their armpits for 2 min. Samples were stored in sterile medical 98 anti-UV glass containers, disinfected by the sampler's helper, anonymously coded, then placed into a 99 second plastic envelope. Individual anonymous data were registered by APHP staff for each coded 100 sample. All samples were transferred within the day of collection from the sampling site to the 101 testing site in coolers that were cleaned and disinfected with a 10% aqueous acetone solution after 102 each use. All samples were stored until they were to be sniffed by the dogs in a minus 20°C freezer 103 and were never manipulated without disposable surgical gloves to prevent contamination.

104 Nasopharyngeal samples (NPS) were collected by a trained nurse, and participants were asked to

self-collect the saliva sample after swishing saliva in their mouths for 30 seconds [6].

- 106 Canine resources
- 107 The dogs involved in this study belong to French fire departments (Service départemental d'Incendie
- 108 et de Secours SDIS of Yvelines and Oise) and to the Ministry of the Interior of the United Arab
- 109 Emirates (provided on the occasion to increase the number of operational dogs involved).
- 110 They all were trained in the same way according to the training protocol we developed in a previous
- 111 publication, with line-ups of positive and negative olfaction cones based on positive reinforcement
- (toys) and validated similarly for their individual sensitivities and specificities [5].
- 113 The welfare of the dogs was fully respected, with toy rewards and a total absence of work-induced
- 114 physical or mental fatigue. This study was carried out in strict accordance with the recommendations
- published in the guide for the care and use of animals edited by French law (articles R214-87 to
- 116 R214-137 of the French Rural Code).

117 Testing protocol

118 The testing sessions took place in a dedicated room (Figures 1) in the Alfort School of Veterinary 119 Medicine. A line-up consisting of 10 olfaction cones was placed in the room. During trials, all the 120 cones contained the unfamiliar samples, so neither the dog handlers, the data recorder nor any of 121 the individuals present knew anything about the positivity/negativity of the samples. Once the dogs 122 had performed the line-up, the cones and the background were cleaned with high pressure vapor, 123 new samples were placed and a new trial cycle could start. For each new sample placement, the person in charge had to wear new disposable gloves (of the same brand during the entire period of 124 125 testing sessions) and a mask in order not to contaminate the olfactory environment. Each line-up was 126 sniffed by at least two dogs in order to mimic a real operational situation.

127 Nasopharyngeal and saliva RT-PCR

For nasopharyngeal and saliva samples, nucleic acid extraction was performed with the MGIEasy Nucleic Acid Extraction Kit (MGI Tech Co, Shenzhen, China) on an MGISP-960 instrument (MGI Tech Co). SARS CoV-2 RNA amplification was performed using the TaqPath[™] COVID-19 CE IVD RT PCR Kit (Thermo Fisher Scientific, Coutaboeuf, France). This technique provides results expressed as a cycle threshold (Ct) for each gene target (ORF1ab, N and S genes) [6].

133 Detection of other pathogens in saliva

134 The detection of other viruses (adenovirus, coronaviruses (229E, HKU1, NL63, and OC43), human 135 metapneumovirus A and B, influenza, influenza A H1, influenza A H3, influenza A H1N1/2009, 136 influenza B, parainfluenza viruses (1, 2, 3, and 4), rhinovirus/enterovirus, respiratory syncytial virus A 137 and B) and intracellular bacteria (Bordetella pertussis, Chlamydophila pneumoniae, and Mycoplasma 138 pneumoniae) was performed in saliva samples with the multiplex test QIAstat-Dx[®] Respiratory SARS-139 CoV-2 Panel QIAStat (Qiagen, Courtaboeuf, France). Briefly, 100 µL of saliva was mixed with 400 µL of 140 NeuMoDx Viral Lysis Buffer (NeuMoDx Molecular, Inc., Ann Arbor, MI). Then 300 µl of the mix was 141 immediately added to the SARS-CoV-2 Panel cartridge placed into the QIAstat Dx Analyzer System 142 (Qiagen). The QIAstat-Dx Analyzer software processes controls, interprets the sample data and 143 provides Ct values for detected targets.

144 Statistical analysis

145 Sample size was calculated assuming that the sensitivity of the index tests was greater than or equal 146 to 60%. To allow sufficient precision ($\pm 10\%$), 93 subjects with positive nasopharyngeal RT-PCR results 147 were needed in each of the two subgroups (symptomatic and asymptomatic participants). To 148 account for samples excluded for technical reasons, a sample size of 110 subjects with positive 149 nasopharyngeal RT-PCR results was needed in each of these subgroups. As preliminary results 150 indicate that viral loads were not different between symptomatic and asymptomatic patients, the 151 scientific committee of the study, during a planned meeting on December 16, 2020, recommended performing the analysis as soon as 93 subjects with positive nasopharyngeal RT-PCR results were 152 153 included, whether symptomatic or asymptomatic.

RT-PCR results were considered positive if at least one gene was detected. For the RT-PCR technique,
the Ct values reported are those for the ORF1a gene, and if not amplified, for the N gene (and for the
S gene if the N gene was not amplified).

An uncertain canine detection test (the dog shows great interest in the sample, but does not immediately sit down) was considered positive. For samples that were processed by three or more dogs, only the results of two dogs were recorded at random. A sample was considered positive if both dogs marked the sample, and negative in all other cases.

161	Quantitative data were expressed as medians [interquartile range], and qualitative data as numbers
162	(percentages). The diagnostic accuracy of the index tests was evaluated by calculating sensitivity and
163	specificity. Confidence intervals were calculated by the exact binomial method. Subgroup analyses
164	were performed according to: i) the presence of symptoms on the day of testing, ii) the Ct value of
165	the nasopharyngeal RT-PCR, expressed as low (at least one of the 3 targets with $Ct \le 28$, i.e. high viral
166	shedding) or high (all 3 targets with Ct > 28, i.e. low viral shedding), iii) the consumption of alcohol,
167	coffee, food and smoking or tooth brushing before sample collection and iv) proven previous
168	infection with SARS-CoV-2.
169	Sensitivity analyses were performed considering 6 alternate criteria for positivity for the reference
170	standard: i) \geq 2 positive targets with nasopharyngeal RT-PCR, ii) \geq 1 positive target with
171	nasopharyngeal RT-PCR and at least one of the 3 targets with Ct < 32, iii) \geq 1 positive target with
172	saliva RT-PCR, iv) \geq 1 positive target with either nasopharyngeal or saliva RT-PCR, v) \geq 1 positive
173	target with either nasopharyngeal or saliva RT-PCR and at least one of the 3 targets with Ct < 32 and
174	vi) nasopharyngeal antigen test.

Quantitative variables were compared with Wilcoxon's test, with a significance level of 5%. The
sensitivity and specificity of canine detection and nasopharyngeal antigen tests were compared with
McNemar's test. The statistical analysis was performed using R software (http://cran.r-project.org/).
The reporting of results followed the Standards for Reporting Diagnostic accuracy studies (STARD
2015) guideline [7].

181 **RESULTS**

182 The flow of participants is described in Figure 2. Between March 16 and April 9, 2021, 516 183 participants were included in SALICOV-APHP study, 403 of whom agreed to provide an axillary 184 sample. Among them, 68 were excluded; 335 patients were thus analyzed. The proportions of 185 females and males were similar and median age of study participants was 35 years [25-49] (Table 1). 186 The reasons expressed by the individuals to be tested were the presence of symptoms (41.2%), being 187 contact cases (45.7%) or others (travel, voluntary testing, etc., 13.1%). Among the participants, 43% 188 presented with symptoms on the day of testing. The median time since the last contact and since the 189 first clinical symptom was 5 days [0-7] and 2 days [1-3], respectively.

190 Among the 335 participants, 109 (32.5%) tested positive on nasopharyngeal RT-PCR. The sensitivities 191 and specificities for all the participants and according to the presence/absence of symptoms are 192 presented in Table 2. The overall sensitivity of canine detection was 97% (95% Cl, 92 to 99), reaching 193 100% (95% CI: 89-100) for asymptomatic individuals. The specificity was 91% (95% CI, 87 to 95), 194 reaching 94% (95% CI, 90 to 97) for asymptomatic individuals. The PPV and NPV (Positive and 195 Negative Predictive Values) were 84% (95% CI, 77 to 90) and 99% (95% CI, 85 to 99), respectively. The 196 sensitivity and specificity analysis of the diagnostic accuracy of the canine detection, as compared to 197 other reference tests, is presented in Table 3.

198 Measures of diagnostic accuracy did not differ according to different subgroups: with or without a 199 medical history of COVID, and having received medical treatment or not, tobacco, alcohol or coffee, 200 and gender (data not shown). In addition, sensitivities were similar for high (Ct \leq 28) and low (Ct >201 28) viral loads: 97% (95% Cl, 92 to 99) and 100% (95% Cl, 59 to 100), respectively.

Among the 234 participants who agreed to the nasopharyngeal antigenic test, the sensitivity of canine detection was greater than that of the antigenic test (97% CI: 91 to 99 versus 84% CI: 74 to 90,

204 p=0.006), but the specificity was lower (90% CI: 84 to 95 versus 97% CI: 93 to 99, p=0.016).

To assess if the infection with other respiratory viruses could interfere with canine olfaction, saliva samples were tested with a multiplex PCR assay. Remainning saliva samples were available for 283 out of 335 participants. Out of these 283 saliva samples, 87 saliva were positive for SARS-CoV-2 and

208	25 samples were positive for another pathogen : $rhinovirus/enterovirus$ (n = 11), human
209	coronaviruses (3 OC43 and 2 NL63), parainfluenza 3 (n = 2), bocavirus (n = 1), VRS (n = 2), bocavirus /
210	VRS (n = 1), Influenza A H1 (n = 1), human metapneumovirus (n = 1), Bordetella pertussis (n = 1).
211	Three co-infection with SARS-CoV-2 was identified. Out of 20 individuals tested negative for SARS-
212	CoV-2 in NPS samples but found positive with canine olfaction, 17 samples were tested for multiplex
213	detection in saliva. Fourteen had no other pathogene, two were positive for a coronavirus (NL63 and
214	OC43) and one was positive for SARS-CoV-2. For the diagnosis of viral respiratory infection (other
215	than SARS-CoV-2 infection), the sensitivity of canine detection was 20% (95% CI, 7% -41%) and the
216	specificity was 62% (95% CI, 56% -68%).

- 217
- 218

219 **DISCUSSION**

- 220 Our results show the excellent sensitivity of SARS-CoV-2 detection by dogs using nasopharyngeal RT-
- 221 PCR as the reference for comparison. These results are consistent with the results obtained
- previously in proof of concepts studies using sweat in hospitalized patients [5,8–11].
- 223 To our knowledge, this study is the first one carried out prospectively in the context of SARS-CoV-2
- screening and the first comparing dog detection and antigenic tests.

225 The results detailed showed no real difference in the sensitivity observed in the different subgroups:

sensitivity is always over 95% when specificity ranges from 83% to 95%.

The results obtained by canine detection using sweat samples are comparable to those of nasopharyngeal antigenic tests. However, canine detection using sweat samples is less invasive than antigenic tests on nasopharyngeal samples. Thus, the detection of SARS-CoV-2 infection by dogs

230 could be an alternative to antigenic tests.

Dog screening for SARS-CoV-2 seems specific for COVID-19 infection and not for viral infections in general since only 2 among the 17 saliva samples in false positive patients were positive for a virus other than SARS-CoV-2. Note, however, that in both cases, it was a coronarovirus. We do not have

- enough patients negative for SARS-CoV-2 and positive for other coronaviruses to know whether the
- 235 canine detection is specific for SARS-CoV-2 or for all coronaroviruses.

Screening people directly, without going through sweat or saliva samples, could also be considered; the advantage would certainly be increased speed. The disadvantage is the fear of dogs exhibited by a significant number of individuals and the risk of dog contamination, which is not possible with the system we have used. Direct detection by dogs should be further evaluated.

240

A limitation of non-invasive detection of SARS-CoV-2 infection by canine olfaction is the availability of trained dogs in this approach in light of the very significant needs if canine detection were to be considered as an alternative to antigenic tests. Another limitation is the need for certification of the dogs used for SARS-CoV-2 detection because of the risk of involving dogs whose diagnostic performance is inferior to those shown here. At the time of the study, there was no delta viriants detected, but there is no reason to believe that the results would have been different in the presence of the delta variants.

248 To conclude, the results obtained in our prospective study involving 335 individuals who presented 249 voluntarily in one of the APHP testing centers in Paris support the use of canine olfaction as an 250 alternative to antigenic tests. Canine testing is non-invasive and provides immediate and reliable 251 results. As for antigenic tests, positive results must be confirmed by RT-PCR, especially for variant 252 screening. Further studies will be focused on direct sniffing by dogs to evaluate sniffer dogs for mass 253 pre-test in airports, harbors, railways stations, cultural activities or sporting events. Axillary sweat 254 testing could remain useful for small population testing or for mobile units acting on local clusters as 255 an alternative to antigenic tests.

256

257

258 Contributors

259 Study concept and design: D.G., C.D., S.K., J.L.G., J.M.T.; Patients and controls recruitment: L. C., C.E.;

260 Data collection: C.G., C.J., V.R., L.D., G.A., S.D., A.G., M.M.; Analysis and interpretation of data: C.E,

261 J.M.T., D.G.; Drafting the manuscript: D.G., J.M.T. All the authors read and approved the final version

of the manuscript. The authors assume responsibility for the accuracy and completeness of the data

and analyses, as well as the adherence of the trial, its analyses and this report to the protocol.

264

265 Funding

- 266 The trial was supported by a grant from the French Ministry of Health, Region Ile de France and
- 267 Assistance Publique-Hôpitaux de Paris Foundation
- 268
- 269 Declaration of interests
- 270 All authors declare no competing interests
- 271

272 Data sharing

- A data sharing statement provided by the authors is available with the full text of this article.
- 274 Acknowledgments We thank Quentin MUZZIN, Caroline ERDEVEN, Didier ROISSE, Nicolas DIRN,
- 275 Clément LEVERT, Erwan BRETON, Arnaud GALTAT, Fatma AL JASMI, Jamel ALHANAEE and Manea AL
- 276 BLOOSHI for their support in conducting this study, Naim Bouazza and Frantz Foissac for proofreading
- 277 the manuscript
- 278

280 References

- Aksenov AA, Gojova A, Zhao W, Morgan JT, Sankaran S, Sandrock CE, et al. Characterization of
 volatile organic compounds in human leukocyte antigen heterologous expression systems: a
 cell's "chemical odor fingerprint." Chembiochem. 2012 May 7;13(7):1053–9.
- Aksenov AA, Sandrock CE, Zhao W, Sankaran S, Schivo M, Harper R, et al. Cellular Scent of
 Influenza Virus Infection. ChemBioChem. 2014;15(7):1040–8.
- Abd El Qader A, Lieberman D, Shemer Avni Y, Svobodin N, Lazarovitch T, Sagi O, et al. Volatile
 organic compounds generated by cultures of bacteria and viruses associated with respiratory
 infections. Biomed Chromatogr. 2015 Dec;29(12):1783–90.
- Schivo M, Aksenov AA, Linderholm AL, McCartney MM, Simmons J, Harper RW, et al. Volatile
 emanations from in vitro airway cells infected with human rhinovirus. J Breath Res. 2014
 Sep;8(3):037110.
- Grandjean D, Sarkis R, Lecoq-Julien C, Benard A, Roger V, Levesque E, et al. Can the detection
 dog alert on COVID-19 positive persons by sniffing axillary sweat samples? A proof-of-concept
 study. PLOS ONE. 2020 déc;15(12):e0243122.
- Kernéis S, Elie C, Fourgeaud J, Choupeaux L, Delarue SM, Alby M-L, et al. Accuracy of saliva and
 nasopharyngeal sampling for detection of SARS-CoV-2 in community screening: a multicentric
 cohort study. Eur J Clin Microbiol Infect Dis. 2021 Aug 3;
- Bossuyt PM, Cohen JF, Gatsonis CA, Korevaar DA, STARD group. STARD 2015: updated reporting
 guidelines for all diagnostic accuracy studies. Ann Transl Med. 2016 Feb;4(4):85.
- Hag-Ali M, AlShamsi AS, Boeijen L, Mahmmod Y, Manzoor R, Rutten H, et al. The detection dogs
 test is more sensitive than real-time PCR in screening for SARS-CoV-2. Commun Biol. 2021 Jun
 3;4(1):1–7.
- Sarkis R, Lichaa A, Mjaess G, Saliba M, Selman C, Lecoq-Julien C, et al. New method of screening
 for COVID-19 disease using sniffer dogs and scents from axillary sweat samples. J Public Health
 (Oxf). 2021 Jun 23;fdab215.
- Angeletti S, Travaglino F, Spoto S, Pascarella MC, Mansi G, De Cesaris M, et al. COVID-19 sniffer
 dog experimental training: Which protocol and which implications for reliable sidentification? J
 Med Virol. 2021 Oct;93(10):5924–30.
- Jendrny P, Schulz C, Twele F, Meller S, von Köckritz-Blickwede M, Osterhaus ADME, et al. Scent
 dog identification of samples from COVID-19 patients a pilot study. BMC Infect Dis. 2020 Jul
 23;20(1):536.
- 312
- 313
- 314
- 315
- 316
- 317
- 318

319

Tables and Figures

Table 1: Characteristics of study participants. Results are presented as N (%) or medians [interquartile ranges].

	Total (N=335)
Age — yr	35 [25-49]
Females — no. (%)	170 (51)
Contact with a confirmed case — no. (%)	153 (46)
Time since last contact — days	5 [0-7]
Presence of symptoms on the day of testing — no. (%)	143 (43)
Time from symptom onset — days	2 [1-3]
Cough — no. (%)	59 (41)
Headache — no. (%)	63 (44)
Rhinorrhea — no. (%)	53 (37)
Asthenia — no. (%)	58 (41)
Muscle pain — no. (%)	46 (32)
Fever — no. (%)	38 (27)
Diarrhea — no. (%)	107 (8)
Chills — no. (%)	7 (5)
Anosmia — no. (%)	10 (7)
Shortness of breath — no. (%)	7 (5)
Chest pain — no. (%)	7 (5)
Smoking in the last 24 hours — no. (%)	69 (21)
Consumption of alcohol in the last 24 hours — no. (%)	71 (21)
Consumption of coffee in the last hour — no. (%)	53 (16)
Tooth brushing in the last 2 hours — no. (%)	122 (36)
Mouth washing in the last 2 hours — no. (%)	6 (2)

Table 2: Diagnostic accuracy of canine detection as compared to the reference standard (nasopharyngeal RT-PCR, positivity defined as at least one target gene being detected), according to

329 the presence of symptoms in study participants.

330

331

	Total, n	Positive sample, n	Sensitivity (95% Cl*)	Specificity (95% Cl*)
Overall	335	109	97% (92 to 99)	91% (87 to 95)
Symptoms	143	78	96% (89 to 99)	83% (72 to 91)
No symptom	192	31	100% (89 to 100)	94% (90 to 97)

332 *95% CI: 95% Confidence Interval

333

335 Table 3: Sensitivity analysis of the diagnostic accuracy of canine detection, as compared to several

³³⁶ references.

	Total, n	Positive	Sensitivity	Specificity
Reference standard		samples, n	(95% Cl*)	(95% Cl)
NPS RT-PCR \geq 2 targets	335	108	97% (92 to 99)	91% (86 to 94)
Symptoms	143	77	96% (89 to 99)	82% (70 to 90)
No symptoms	192	31	100% (89 to 100)	94% (90 to 97)
NPS RT-PCR \geq 1 target and Ct value < 32	335	107	97% (92 to 99)	90% (86 to 94)
Symptoms	143	76	96% (89 to 99)	81% (69 to 89)
No symptoms	192	31	100% (89 to 100)	94% (90 to 97)
Saliva RT-PCR ≥ 1 target	320	80	90% (81 to 96)	81% (75 to 86)
Symptoms	136	53	96% (87 to 100)	65% (54 to 75)
No symptoms	184	27	78% (58 to 91)	89% (83 to 94)
NPS RT-PCR \geq 1 target or	327	116	92% (86 to 96)	91% (87 to 95)
Saliva RT-PCR ≥ 1 target				
Symptoms	142	79	96% (89 to 99)	84% (73 to 92)
No symptoms	185	37	84% (68 to 94)	95% (90 to 98)
NPS RT-PCR \geq 1 target or	327	112	95% (89 to 98)	91% (87 to 95)
Saliva RT-PCR \geq 1 target and Ct value < 32				
Symptoms	142	78	96% (89 to 99)	83% (71 to 91)
No symptoms	185	34	91% (76 to 98)	95% (90 to 98)
NPS antigen	234	80	95% (88 to 99)	83% (76 to 89)
Symptoms	123	60	97% (88 to 100)	71% (59 to 82)
No symptoms	111	20	90% (68 to 99)	91% (83 to 96)

337 *95% CI : 95% Confidence Interval.

338

Figure 1B: Details of an olfaction cone, with a double-protected sample and no possibility of direct contact with the dog



Figure 1C: Process involving olfaction cones and dog



Figure 1D: Positive marking by a dog, sitting in front of a cone containing a positive sample



Figure 1A: Testing room with its olfaction cones

OLFACTION CONES IN THE TESTING ROOM



Figure 2: Flowchart of the study

